Radiation costs vary widely by delivery, study finds

Oct 08, 2009

When cancer spreads to the bone, radiation treatments can help relieve the pain caused by the tumor. But how best to deliver the radiation may vary widely from one oncologist to the next.

A new analysis from researchers at the University of Michigan Comprehensive Center shows cost also varies widely from one delivery method to the next. Costs can range from around $1,700 for a single treatment with conventional radiation techniques to more than $16,000 for four treatments using a system of radiation delivery called Cyberknife.

"Some of the technologies that have been shown to be safe and effective, but have not been shown to be superior, can cost up to 10 times what a single dose of conventionally delivered radiation costs," says David D. Howell, M.D., assistant professor of at the U-M Medical School and medical director of radiation oncology at the Norval K. Morey Cancer Center in Mt. Pleasant, Mich., part of the U-M Radiation Oncology Network.

Howell presented the results this week at the Symposium in San Francisco, a meeting sponsored by six leading cancer organizations.

Research has shown a single treatment with standard radiation can be equally effective as 10 treatments of standard radiation when it comes to relieving pain associated with cancer that has spread to the bone. Fewer treatments also spare patients and their caregivers from more trips to the radiation department.

But some doctors believe that delivering radiation using more recently developed technologies for radiation delivery, such as stereotactic or Cyberknife, will yield better pain control or fewer side effects in the long term for certain patients. Studies to date have not unequivocally confirmed these views, and research is ongoing.

Most radiation oncologists will consider a variety of factors in choosing a treatment strategy, such as the location and type of cancer, how well it may respond to radiation as well as the patient's previous and current cancer treatment.

"In considering the big picture of patient care and treatments for cancer, safety, efficacy, side effects, the patient's time commitment and comfort all should enter into the mix. Cost is another parameter that should be considered," Howell says.

Source: University of Michigan Health System (news : web)

Explore further: Efficacy of new drug against stem cells that provoke cancer and its metastasis

add to favorites email to friend print save as pdf

Related Stories

Proton therapy lowers chance of later cancers

Sep 22, 2008

Patients who are treated with proton therapy (a specialized type of external beam radiation therapy using protons rather than X-rays to treat cancer) decreases the risk of patients developing a secondary cancer by two-fold, ...

Mammogram most effective 12 months after radiation treatment

Nov 25, 2008

Breast cancer patients who receive breast-conserving therapy and radiation do not need a follow-up mammogram until 12 months after radiation, despite current American Society of Clinical Oncology (ASCO) and National Comprehensive ...

High-dose radiation improves lung cancer survival

Apr 08, 2009

Higher doses of radiation combined with chemotherapy improve survival in patients with stage III lung cancer, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.

Recommended for you

How a common antacid could lead to cheaper anti-cancer drugs

11 minutes ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

Vaccines may make war on cancer personal

23 minutes ago

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University ...

Funding to investigate an alternative to chemotherapy

1 hour ago

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...

Enzyme may be key to cancer progression in many tumors

1 hour ago

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.